In ovarian cancer, MYC amplification is correlated with inactivation in the breast and ovarian cancer susceptibility protein (BRCA) and retinoblastoma-associated protein (RB1) pathways [32]; in endometrial cancer, MYC amplification is associated with low estrogen receptor (ER)/FOXA1 activity and TP53 mutations [33]. Here, RB1 is linked to endometrial cancer.